Skip to content
Inciteful Med

The Diagnosis Trap: Differentiating FHH1 from Parathyroid Tumors

Last updated:

Familial Hypocalciuric Hypercalcemia Type 1 (FHH1) is often misdiagnosed as primary hyperparathyroidism because both cause high blood calcium. A 24-hour urine test and CASR genetic testing can differentiate the two, preventing patients with FHH1 from undergoing ineffective parathyroid surgery.

Key Takeaways

  • • FHH1 and primary hyperparathyroidism both cause high blood calcium but require entirely different treatments.
  • • A 24-hour urine collection to check the CCCR is critical for diagnosing FHH1, which typically shows very low urine calcium.
  • • Low vitamin D, thiazide diuretics, and lithium can alter urine test results and cause a misdiagnosis.
  • • Genetic testing for the CASR gene is the gold standard to confirm FHH1 and prevent unnecessary parathyroid surgery.
  • • Parathyroid surgery does not cure FHH1, and calcium levels will usually rise again after the procedure.

When a blood test shows high calcium and a normal or high Parathyroid Hormone (PTH) level, many doctors immediately suspect Primary Hyperparathyroidism (PHPT) [1][2]. In PHPT, a small non-cancerous tumor on the parathyroid gland is overproducing hormone and needs to be surgically removed.

However, Familial Hypocalciuric Hypercalcemia Type 1 (FHH1) creates a very similar or overlapping blood profile [3][4]. This “biochemical overlap” is a common trap that can lead to misdiagnosis and unnecessary, ineffective surgery [5][6].

Comparing FHH1 and PHPT

Understanding the subtle differences between these two conditions is critical:

Feature FHH1 Primary Hyperparathyroidism (PHPT)
Blood Calcium Mildly to moderately high Mildly to severely high
Parathyroid Hormone (PTH) Normal or slightly high Usually frankly high
Urine Calcium Low (Hypocalciuria) Normal or High
CCCR Result Typically <0.01< 0.01 Typically >0.02> 0.02
Treatment Strategy Observation Parathyroid Surgery

The Key Test: The 24-Hour Urine Collection

To tell these two conditions apart, doctors must look at how much calcium your kidneys are releasing. This is typically done through a 24-hour urine collection to calculate the Calcium-to-Creatinine Clearance Ratio (CCCR), a mathematical formula comparing calcium and creatinine in your blood and urine [7][1].

  • PHPT: The body is trying to get rid of excess calcium, so the urine calcium levels are usually high [1].
  • FHH1: The body thinks the high calcium is “normal,” so the kidneys hold onto it. This results in low urine calcium (hypocalciuria) [1][8].

Understanding the CCCR Numbers

The CCCR result acts like a signpost pointing toward one diagnosis or the other:

  • CCCR less than 0.01: Highly suggestive of FHH1 [7][1].
  • CCCR greater than 0.02: Highly suggestive of PHPT [7][9].
  • The “Gray Zone” (0.01 to 0.02): About 25% of patients fall into this middle ground where the urine test alone cannot give a definitive answer [10][11].

Factors That Can “Muddle” the Results

The urine test is helpful, but it isn’t perfect. Several factors can make PHPT look like FHH1 (causing a falsely low CCCR):

  • Vitamin D Deficiency: If your Vitamin D is low, your body will naturally hold onto calcium, which can make a parathyroid tumor look like FHH1 [7][12].
  • Medications: Thiazide diuretics (often used for blood pressure) and Lithium can lower the amount of calcium in your urine [13][14].
  • Kidney Function: If your kidneys aren’t working at full strength, the CCCR may be less reliable [14].

The Gold Standard: CASR Genetic Testing

Because the urine test has limitations, checking your DNA through genetic testing of the CASR gene is the gold standard for confirmation [15][16].

Finding a mutation in the CASR gene confirms FHH1 and provides a “diagnostic shield” for the rest of your life. This is critical because:

  1. Surgery is Ineffective for FHH1: Removing parathyroid glands does not fix the underlying genetic “thermostat” issue. Most FHH1 patients who have surgery will see their calcium levels climb right back up within a year [5][6].
  2. Family Protection: Once a mutation is found, your relatives (children, siblings, parents) can be tested. This prevents them from also falling into the “misdiagnosis trap” and undergoing unnecessary surgeries [17][18].

A critical note on genetic testing: While a positive test confirms FHH1, it is important to know that up to 20-30% of patients with clinical FHH do not have an identifiable mutation in the CASR, GNA11, or AP2S1 genes [16]. Therefore, a negative genetic test does not completely rule out the condition, and a diagnosis may still be made clinically based on your urine tests and family history.

If your results are in the “gray zone” or if you have a family history of high calcium, you should advocate for genetic testing before agreeing to any surgical procedures [16][7].

Return to the Home Page.

Frequently Asked Questions

Why is FHH1 often misdiagnosed as primary hyperparathyroidism?
Both conditions cause high blood calcium and normal or high parathyroid hormone levels. Doctors may immediately suspect a parathyroid tumor and recommend surgery without checking urine calcium levels first, which is the key to differentiating them.
What is the CCCR test for FHH1?
The Calcium-to-Creatinine Clearance Ratio (CCCR) uses a 24-hour urine collection to measure how much calcium your kidneys are releasing. A CCCR under 0.01 strongly suggests FHH1, while a result over 0.02 points to a parathyroid tumor.
Can medications affect my FHH1 test results?
Yes, medications like thiazide diuretics used for blood pressure, as well as lithium, can lower the amount of calcium in your urine. This can artificially lower your CCCR score and make a parathyroid tumor look like FHH1 on your lab results.
Will removing my parathyroid glands cure FHH1?
No, removing parathyroid glands is ineffective for FHH1 because it does not fix the underlying genetic issue. If a patient with FHH1 has parathyroid surgery, their calcium levels typically rise back up within a year.
Why is genetic testing important if I might have FHH1?
Genetic testing for the CASR gene is the gold standard for confirming FHH1. Finding a mutation proves that parathyroid surgery will not fix your high calcium, and it protects your relatives from undergoing unnecessary procedures.

Questions for Your Doctor

  • • My CCCR result was [X]—how does this compare to the standard cutoff of 0.01 for FHH1?
  • • Was my Vitamin D level corrected before we did the 24-hour urine collection?
  • • Are there any medications I'm taking, like Thiazides or Lithium, that could be making my urine calcium look lower than it actually is?
  • • If we are in a 'gray zone' (0.01 to 0.02), should we proceed with CASR genetic testing before considering any surgical options?
  • • If I have FHH1, how can we document this in my record so I'm not mistakenly treated for a parathyroid tumor in the future?

Questions for You

  • • Have any of my family members had a parathyroid surgery that didn't actually lower their calcium levels?
  • • When I look back at old medical records, was my calcium ever high years ago, even if it wasn't flagged at the time? (FHH1 is usually present from birth).
  • • Am I feeling anxious to 'fix' the high calcium with surgery, or can I wait for genetic confirmation to ensure surgery is truly necessary?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Genetics of hereditary forms of primary hyperparathyroidism.

    English KA, Lines KE, Thakker RV

    Hormones (Athens, Greece) 2024; (23(1)):3-14 doi:10.1007/s42000-023-00508-9.

    PMID: 38038882
  2. 2

    A Hypercalcemic Deception: Uncovering an Unusual Case of Familial Hypocalciuric Hypercalcemia.

    Gandhi SM, Nylen ES

    Cureus 2025; (17(10)):e95514 doi:10.7759/cureus.95514.

    PMID: 41311753
  3. 3

    Identification of a novel large CASR deletion in a patient with familial hypocalciuric hypercalcemia.

    García-Castaño A, Madariaga L, Azriel S, et al.

    Endocrinology, diabetes & metabolism case reports 2018; (2018()).

    PMID: 30530875
  4. 4

    Calcium homeostasis and hyperparathyroidism: Nephrologic and endocrinologic points of view.

    Lemoine S, Figueres L, Bacchetta J, et al.

    Annales d'endocrinologie 2022; (83(4)):237-243 doi:10.1016/j.ando.2022.05.003.

    PMID: 35598638
  5. 5

    Novel mutations of the calcium-sensing receptor impede differential diagnosis of primary hyperparathyroidism and familial hypocalciuric hypercalcemia.

    Bhangu JS, Baumgartner-Parzer S, Hargitai L, et al.

    Gland surgery 2022; (11(1)):12-22 doi:10.21037/gs-21-577.

    PMID: 35242665
  6. 6

    Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients.

    Mouly C, Vargas-Poussou R, Lienhardt A, et al.

    Clinical endocrinology 2020; (93(3)):248-260 doi:10.1111/cen.14211.

    PMID: 32347971
  7. 7

    Think twice: a rare calcium sensing receptor mutation and a new diagnosis of familial hypocalciuric hypercalcaemia.

    Tellam JJ, Abdulrasool G, Ciin LCH

    Endocrinology, diabetes & metabolism case reports 2020; (2020()).

    PMID: 32698162
  8. 8

    Parathyroid hormone-dependent familial hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR.

    Mahajan A, Buse J, Kline G

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2020; (31(1)):203-207 doi:10.1007/s00198-019-05170-9.

    PMID: 31641801
  9. 9

    Is biochemical screening enough to guide calcium-sensing receptor gene mutational analysis when diagnosing familial hypocalciuric hypercalcemia? A retrospective study.

    Flaris AN, Julsrud TO, Vierkant RA, et al.

    Surgery 2025; (177()):108840 doi:10.1016/j.surg.2024.07.077.

    PMID: 39389817
  10. 10

    CALCIUM CREATININE CLEARANCE RATIO IS NOT HELPFUL IN DIFFERENTIATING PRIMARY HYPERPARATHYROIDISM FROM FAMILIAL HERPERCALCEMIC HYPOCALCIURIA: A STUDY OF 1000 PATIENTS.

    Moore EC, Berber E, Jin J, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; doi:10.4158/EP-2018-0350.

    PMID: 30289313
  11. 11

    Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives.

    Htoo STY, Cusano NE

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(11)):1488-1494 doi:10.1016/j.eprac.2025.07.009.

    PMID: 40683368
  12. 12

    Primary hyperparathyroidism versus familial hypocalciuric hypercalcemia: a challenging diagnostic evaluation in an adolescent female.

    Tosur M, Lopez ME, Paul DL

    Annals of pediatric endocrinology & metabolism 2019; (24(3)):195-198 doi:10.6065/apem.2019.24.3.195.

    PMID: 31607113
  13. 13

    The influence of thiazide intake on calcium and parathyroid hormone levels in patients with primary hyperparathyroidism.

    Riss P, Kammer M, Selberherr A, et al.

    Clinical endocrinology 2016; (85(2)):196-201 doi:10.1111/cen.13046.

    PMID: 26921840
  14. 14

    Is routine 24-hour urine calcium measurement useful during the evaluation of primary hyperparathyroidism?

    Li SR, McCoy KL, Levitt HE, et al.

    Surgery 2022; (171(1)):17-22 doi:10.1016/j.surg.2021.04.055.

    PMID: 34325903
  15. 15

    CASRdb: A Publicly Accessible Comprehensive Database for Disease-Associated Calcium-Sensing Receptor Variants.

    Charoenngam N, Wattanachayakul P, Mannstadt M

    The Journal of clinical endocrinology and metabolism 2025; (110(2)):297-302 doi:10.1210/clinem/dgae769.

    PMID: 39484850
  16. 16

    Familial hypocalciuric hypercalcemia in an index male: grey zones of the differential diagnosis from primary hyperparathyroidism in a 13-year clinical follow up.

    Zajíčková K, Dvořáková M, Moravcová J, et al.

    Physiological research 2020; (69(Suppl 2)):S321-S328 doi:10.33549/physiolres.934522.

    PMID: 33094630
  17. 17

    Case Report: Unusual Presentations of Loss-of-Function Mutations of the Calcium-Sensing Receptor.

    Palmieri S, Grassi G, Guarnieri V, et al.

    Frontiers in medicine 2021; (8()):809067 doi:10.3389/fmed.2021.809067.

    PMID: 35141253
  18. 18

    Neonatal Hypocalcemic Seizures in Offspring of a Mother With Familial Hypocalciuric Hypercalcemia Type 1 (FHH1).

    Dharmaraj P, Gorvin CM, Soni A, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(5)) doi:10.1210/clinem/dgaa111.

    PMID: 32150253

This page explains diagnostic differences between FHH1 and parathyroid tumors for educational purposes only. Always consult an endocrinologist or medical geneticist regarding your specific lab results and treatment plan.

Stay up to date

Get notified when new research about Familial hypocalciuric hypercalcemia type 1 is published.

No spam. Unsubscribe anytime.